Joseph Eron
@joseph_eron
Followers
509
Following
16
Media
26
Statuses
278
Joined January 2015
Terrific! Congratulations to the authors including David van Duin @UNC_ID @uncglobalhealth.
Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. ✅ Just Accepted.🆓 Freely Available.🔗
0
2
3
Solar panels in Malawi to support clinical and translational research and our mother (Earth).
0
0
12
RT @Drbenderignacio: Thrilled to be a part of this @ACTGNetwork #COVID19 @uw_positive .Safety and Efficacy of Combination SARS-CoV-2 Neutr….
acpjournals.org
Background: Development of safe and effective SARS-CoV-2 therapeutics is a high priority. Amubarvimab and romlusevimab are noncompeting anti–SARS-CoV-2 monoclonal antibodies with an extended half-l...
0
4
0
Large NIH study, Led by Steve Grinspoon and Pam Douglas, in partnership with ACTG, demonstrates that statin therapy in low and mod CVD-risk people with HIV decreases CVD outcomes. @ACTGNetwork
niaid.nih.gov
A National Institutes of Health (NIH) clinical trial was stopped early because a daily statin medication was found to reduce the increased risk of cardiovascular disease among people living with HIV...
2
5
12
RT @mfm_ID_MD: Looking forward to the launch of this innovative training program @UNC_ID . Applicants for combined ID/EIS training need t….
0
19
0
Looking forward to being in-person!!.
Join @joseph_eron and Princy N. Kumar, MD on 4/11 in DC for 'CROI 2023 Update: What Did We Learn?'. Earn 2.50 AMA, ANCC, and ACPE credits. Dinner provided by CCO. Register for free:
0
0
0
RT @CCO_Education: Join @joseph_eron and Princy N. Kumar, MD on 4/11 in DC for 'CROI 2023 Update: What Did We Learn?'. Earn 2.50 AMA, ANCC,….
clinicaloptions.com
CROI 2023 Update: What Did We Learn?
0
1
0
Infectious Diseases and EIS great combination.
Take your 1st step towards #IDEISFellowship. Apply to EIS: The joint ID/EIS fellowship uses the existing EIS & ID fellowship applications. Applicants must apply separately to both the EIS & the ID fellowship programs. Learn more:
0
0
4
Critically important paper for HIV providers as MPox potentially becomes a uncommon endemic infection in people who have risk. Also vaccinate people with risk!
pubmed.ncbi.nlm.nih.gov
None.
0
1
2
RT @LizHighleyman: Potentially the next step in the evolution of #HIV treatment: @GileadSciences' lenacapavir (Sunlenca) + 2 broadly neutra….
poz.com
90% of people who received an injection of lenacapavir plus two broadly neutralizing antibodies maintained viral suppression for six months.
0
4
0
RT @uncglobalhealth: National guidelines may have played a role in #equitable access to new therapy. #racial #disparities #HIV #ART Check….
0
3
0
Amen! Our downstream VALUE to patients, health care systems and public health is unrecognized or unappreciated and therefore uncompensated. What "wRVU" is assigned to curing HCV (see last tweet). atCVDH(if heaven has twitter) would likely have advice.
pnhp.org
Share on FacebookShare on Twitter As told to Jonathan Michels Indy Week (Durham, N.C.), June 19, 2019 The Triangle’s health…read more
@joseph_eron @UNC_ID @uncglobalhealth This only solves probably 30-40% of the problem. >45% of ID fellows who turn into ID clinician may not have loans( FMGs etc). Unless there is a fair compensation to ID clinicians and regulations to hire ID clinicians systemwide for quality of care this is probably just a patch!.
0
0
2
Yesterday in clinic we saw our one of our older patients living with HIV for 30 + years who just had their first great, great grandchild. Seriously, who would have dreamed that up 30 years ago.
15
92
885
Gift wrapped "cure package" for hard to reach (wait no - HARDLY reached) patients. Another Infectious Disease service with incredible down stream value to the patient, healthcare system and public health (but no wRVUs).
0
0
5
Have to agree with @jrarribas though more data to come with DTG/DRVboosted. Two very high barrier agents. LEN and CAB both are not in that category. CROI will be great this year-go if you can.
#HIVTwitter #IDtwitter Someone with RPV resistance, no INSTI mutations, desperately wants to be on a pill-free inj ART. Trogarzo can’t do due to 2-weekly infusion need. Would you trust CAB/Lencapavir? If not why not? @PaulSaxMD @joseph_eron @drlaurajwaters @sebpoule @jrarribas.
1
0
2
Critically important @UNC_ID @uncglobalhealth.
Loan repayment program seeks to bolster infectious disease - we need Infectious Disease physicians more than ever! #WeAreID @IDSAInfo @LevyCIMAR @McQHoya81 @CarlosdelRio7 @DrJeanneM @DMAronoff
1
1
1
Congratulations Cecilia - critical faculty member in ID Division and key investigator for the IGHID.
And she just submitted her first nih grant as PI! @UNCMalawi.
0
0
3
PS - actually read the paper (I know, crazy). No impact of CMV treatment or CMV EOD on mortality. So causal or a more subtle marker of immune deficiency? @PaulSaxMD.
@PaulSaxMD @CIDJournal @LeviLevilaura Fascinating - not our standard to test CMV DNA w/o specific symptoms in PWH presenting with late stage disease but just took care of PWH w CMV DNA > 1,000,000. Is it standard at other places?.
1
0
0
